May 16, 2019
4D pharma’s Chron’s treating Thetanix meets objective
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Crohn`s disease
March 6, 2017
TiGenix waits for final EMA nod for its Crohn’s disease drug
TiGenix has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Crohn’s disease drug Cx601 in 2017.
December 21, 2016
Takeda makes EUR10 million equity investment in TiGenix
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
October 20, 2016
Esperite starts developing inflammatory bowel disease therapies; Starts with Crohn`s disease
Esperite`s business unit The Cell Factory in collaboration with Women`s and Children`s Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).